Nuclera
Latest round
- Series C
Last raised
- Oct 2024
Total raised
- $133M
Investors
- 12
About Nuclera
Based in the UK, Nuclera Ltd operates as a biotech company that develops a digital platform to enable protein printing. Based in Cambridge, UK, and founded in 2013 by CEO Michel Chen, CFO Jiahao Huang, and CTO Gordon Mclnroy, Nuclera Ltd operates as a biotechnology company that accelerates the protein expression workflows through desktop enzymatic protein and gene synthesis. K. Goh Holdings and British Business Bank. The company product line includes eProtein synthesis, a desktop bioprinter that delivers proteins through the combination of cell-free technologies and digital microfluidics; eDrop digital microfluidics, a programmable lab-on-a-chip technology that employs eProtein and eDNA synthesis bio-inks to make drug discovery workflows accessible on the benchtop. Nuclera generates revenue by selling its eProtein Discovery benchtop bioprinter, smart cartridges, and related protein-synthesis consumables to biotech and pharmaceutical researchers seeking faster, automated protein access.
Who invested in Nuclera
12 investors across 3 rounds
See all investors in Nuclera
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nuclera
Who invested in Nuclera?
Nuclera has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nuclera raised?
Nuclera has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Nuclera last raise money?
Nuclera's most recent round on record is a Series C, in Oct 2024.
What does Nuclera do?
Based in the UK, Nuclera Ltd operates as a biotech company that develops a digital platform to enable protein printing.
Where is Nuclera headquartered?
Nuclera is headquartered in Cambridge, UK.
Which VCs invest in companies like Nuclera?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Nuclera's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Nuclera? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.